论文信息 - Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. - 字舞流文

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.

A. Mansfield | Michael Thomas | R. Doebele | G. Curigliano | L. Paz-Ares | Dong-Wan Kim | B. Cho | Dae-Ho Lee | S. Gadgeel | B. Besse | G. Lopes | Matthew H Taylor | V. Subbiah | C. Baik | P. Cassier | Stephen V. Liu | C. Turner | J. Gainor | E. Garralda | Hui Zhang | V. Zhu | D. Tan | C. Clifford | M. Palmer | Jennifer M. Green | Matthew H. Taylor | Jennifer Green